Body fat abnormality in HIV-infected children and adolescents living in europe: Prevalence and risk factors

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 3, 2012, Pages 314-324

  Alam, Naufil ^a   Cortina Borja, Mario ^a   Goetghebuer, Tessa ^b   Marczynska, Magdalena ^c   Vigano, Alessandra ^d   Thorne, Claire ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Adolescents; Antiretroviral therapy; Children; Fat abnormality; Lipodystrophy syndrome

Indexed keywords

DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BELGIUM; BODY FAT; BODY FAT ABNORMALITY; BODY MASS; CHILD; CROSS-SECTIONAL STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; ETHNICITY; EUROPE; FACE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LIPOATROPHY; LIPOHYPERTROPHY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; POLAND; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT DURATION; TRUNK;

ADOLESCENT; ANTI-HIV AGENTS; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CHOLESTEROL; CROSS-SECTIONAL STUDIES; EUROPE; HIV; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; PREVALENCE; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84859374751     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31824330cb     Document Type: Article

References (69)

1. Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001; 15: 231-239. (Pubitemid 32142299)
2. Carr A, Samaras K, Thorsidottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353: 2093-2099. (Pubitemid 29278477)
3. Saves M, Francois R, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002; 34: 1396-1405. (Pubitemid 34507951)
4. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleosideanalogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002; 34: 649-657. (Pubitemid 34165328)
5. Shlay JC, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005; 38: 147-155. (Pubitemid 40189321)
6. Pujari SN, Dravid A, Naik E, et al. Lipodystrophy and dyslipidemia among patients taking first-line World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr. 2005; 39: 199-202. (Pubitemid 40741119)
7. George JA, Venter WDF, Van Deventer HE, et al. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses. 2009; 25: 771-781.
8. European Paediatric Lipodystrophy Group. Antiretroviral therapy fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004; 18: 1443-1451.
9. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIVinfected children. J Acquir Immune Defic Syndr. 2005; 40: 161-168. (Pubitemid 41395714)
10. Sanchez-Torres AM, Munoz-Muniz R, Madero R, et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virusinfected children. Eur J Pediatr. 2005; 164: 271-276. (Pubitemid 40613041)
11. Ene L, Goetghebuer T, Hainaut M, et al. Prevalence of lipodystrophy in HIV-infected children-a cross-sectional study. Eur J Pediatr. 2007; 166: 13-21. (Pubitemid 44900517)
12. Amaya RA, Kozinetz CA, McMeans A, et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002; 21: 405-410. (Pubitemid 34532934)
13. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS. 2003; 17: 1319-1327. (Pubitemid 36819846)
14. Parakh A, Prakash-Dubey A, Kumar A, et al. Lipodystrophy and metabolic complications of highly active antiretroviral therapy. Indian J Pediatr. 2009; 76: 1017-1021.
15. Resino S, Micheloud D, Lorente R, et al. Adipokine profiles and lipodystrophy in HIV-infected children during the first 4 years on highly active antiretroviral therapy. HIV Med. 2011; 12: 54-60.
16. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003; 361: 726-735.
17. UNAIDS. AIDS epidemic update 2010. In: AIDS Epidemic Update. Geneva, Switzerland: UNAIDS; 2010: 16-62.
18. WHO. Towards Universal Access; Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Geneva, Switzerland: HIV/AIDS Department, World Health Organization; 2009.
19. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001; 345: 1522-1528. (Pubitemid 33144917)
20. Gibb DM, Duong T, Tookey PA, et al. Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland. BMJ. 2003; 327: 1019-1023. (Pubitemid 37357464)
21. Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. Mortality in HIVinfected and uninfected children of HIV-infected and uninfected mothers in rural Uganda. J Acquir Immune Defic Syndr. 2006; 41: 504-508.
22. PENTA. Paediatric European Network for Treatment of AIDS (PENTA) treatment guidelines. 2009. Available at: http: //www.pentatrials.org/-guide09. pdf. Accessed January 13, 2012.
23. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2009.
24. Italian Multicentre Study. Epidemiology, clinical features, and prognostic factors of paediatric HIV infection. Lancet. 1988; 332(8619): 1043-1045.
25. Epidemiology of HIV infection in children in Italy. The Italian Register for HIV Infection in Children. Acta Paediatr Suppl. 1994; 400: 15-18.
26. Tanner JM. Growth At Adolescence: With a General Consideration of the Effects of Hereditary and Enviromental Factors Upon Growth and Maturation From Birth to Maturity. 2nd ed. Oxford: Blackwell Scientific; 1962.
27. Castro G, Ward JW, Slutker L, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; Vol. 41.
28. Caldwell MB, Oxtoby MJ, Simonds RJ, et al. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994; 43: 1-10.
29. Schneider E, Whitmore S, Glynn KM, et al. Revised surveillance case definitions for HIV infection among adults, adolescents and children aged ,18 months and for HIV infection and AIDS among children aged 18 months to ,13 years-United States, 2008. MMWR Recomm Rep. 2008; 57: 1-8.
30. Jolliffe CJ, Janssen I. Distribution of lipoproteins by age and gender in adolescents. Circulation. 2006; 114: 1056-1062. (Pubitemid 44358882)
31. Jaquet D, Levine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS. 2000; 14: 2123-2128.
32. Arpadi SM, Cuff PA, Horlick MN, et al. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4 B-lymphocyte count and CD4 B-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 2001; 27: 30-34. (Pubitemid 32587239)
33. Bockhorst JL, Ksseiry I, Toye M, et al. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J. 2003; 22: 463-465. (Pubitemid 36578754)
34. Young J, Weber R, Rickenbach M, et al. Lipid profiles for antiretroviralnaive patients starting PI- and NNRTI-based therapy in the Swiss HIV Cohort Study. Antivir Ther. 2005; 10: 585-591. (Pubitemid 41224950)
35. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France 1999. Clin Infect Dis. 2000; 31: 1482-1487.
36. Mauss S, Berger F, Carls H, et al. Rapid development of central adiposity after postexposure prophylaxis with antiretroviral drugs: a proof of principle? AIDS. 2003; 17: 944-945. (Pubitemid 36547679)
37. Riddle TM, Kuhel DG, Woollet LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem. 2001; 276: 37514-37519.
38. Riddle TM, Schildmeyer NM, Phan C, et al. The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J Lipid Res. 2002; 43: 1458-1463.
39. Hruz PW, Murata H, Qui H, et al. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes. 2002; 51: 937-942. (Pubitemid 34438334)
40. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999; 13: 2493-2505. (Pubitemid 30038027)
41. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000; 14: 37-49. (Pubitemid 30072076)
42. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001; 15: 1389-1398. (Pubitemid 32662290)
43. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999; 13: 2261-2267. (Pubitemid 29531445)
44. Carr A, Samaras K, Chisholm DJ, et al. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998; 351: 1881-1883. (Pubitemid 28279721)
45. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002; 359: 1026-1031. (Pubitemid 34286541)
46. Martinez E, Gatell J. Metabolic abnormalities and use of HIV-1 protease inhibitors. Lancet. 1998; 352: 821-822. (Pubitemid 28404583)
47. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003; 17: 1329-1338. (Pubitemid 36819847)
48. Pace CS, Martin AM, Hammond EL, et al. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003; 8: 323-331. (Pubitemid 37101636)
49. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000; 14: 1309-1316. (Pubitemid 30459502)
50. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001; 357: 592-598. (Pubitemid 32179612)
51. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002; 29: 21-31. (Pubitemid 34094303)
52. Moyle GJ, Sabin CA, Cartledge J, et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006; 20: 2043-2050. (Pubitemid 44611057)
53. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIVinfected patients 2 years after switching from a thymidine analogue to abacavir; the MITOX Extension Study. AIDS. 2004; 18: 1029-1036. (Pubitemid 38591194)
54. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006; 42: 562-571.
55. Shlay JC, Sharma S, Peng G, et al. The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009; 51: 298-304.
56. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349: 1993-2003.
57. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002; 16: 2447-2454. (Pubitemid 35471693)
58. Seminari E, Tinelli C, Minoli L, et al. Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV-positive patients. Antivir Ther. 2002; 7: 175-180. (Pubitemid 36427142)
59. Bogner JR, Vielhauer V, Beckman RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001; 27: 237-244. (Pubitemid 32661964)
60. Mutimura E, Stewart A, Rheeder P, et al. Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2007; 46: 451-455. (Pubitemid 350098696)
61. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007; 4: 106.
62. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003; 32: 48-56. (Pubitemid 36091484)
63. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003; 163: 427-436. (Pubitemid 36241019)
64. Sanches S. Facial lipoatrophy appearances are not deceiving. J Assoc Nurses AIDS Care. 2009; 20: 169-175.
65. Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res. 2005; 14: 981-990. (Pubitemid 40685222)
66. Blanche S, Newell ML, Mayaux MJ, et al. Morbidity and mortality in European children vertically infected by HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 14: 442-450. (Pubitemid 127610754)
67. Plankey M, Bacchetti P, Jin C, et al. Self-perception of body fat changes and HAART adherence in the women's interagency HIV study. AIDS Behav. 2009; 13: 53-59.
68. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001; 15: 2441-2444. (Pubitemid 34014613)
69. Dollfus C, Blanche S, Trocme N, et al. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents. HIV Med. 2009; 10: 263-268.